Pathology Service Studies & Research Findings
Pathology Service Studies & Research Findings - Peter MacCallum Cancer Centre
| • Diagnostic molecular test development • Predicting response to hormonal and chemotherapy in patients with in situ and invasive breast cancer in the neoadjuvant setting • Genotyping the AOCS cohort for BRCA status • Mammographic density and breast cancer • Familial breast cancer • Genetic and epigenetic determinants of response to cancer therapy • Profiling of DNA repair in cancer. • Rapid high resolution melting assays for mutation and methylation detection • Novel diagnostics via nanoscaled biosensors. • Somatic DNA methylation and cancer predisposition. • JAK 2 quantitation in myeloproliferative disorders and normal donors • P53 mutation status in myeloma patients on new biological agents • Coagulation assessments and biomarker development in myeloma • Microparticle assessment as a thrombogenic marker in haematological and solid tumours • Immunophenotyping as a response marker for MDS patients on demethylating agents • P53 assessment in diffuse large cell lymphoma (ALLG clinical trial, substudy) • C-Kit mutation assessment in CBF-AML (ALLG clinical trial, substudy) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Professor Stephen Fox • Translational pathology • Translational research in breast cancer • Fat and Breast Cancer: Aromatase, p53 and HIF-1alpha • Personalised breast cancer risk assessment for high risk women • Family study of the genetic and environmental causes and outcomes of early-onset breast cancer • Familial male breast cancer • Biomarker Validation testing • Ovarian cancer as related to germline BRCA1 and BRCA2 mutations. Dr David Westerman • Assessment of thrombogenic biomarkers including microparticle assessment in myeloma patients treated with IMIDS • Assessment of the utility of P53 mutation testing in myeloma patients treated with IMIDS • Immunophenotyping as a diagnostic method for MDS, and its utility as a predictor of disease response to new biological agents. One of these studies is linking with an ALLG phase II MDS treatment trial • Utility of CD200 as a differentiator in the diagnosis of NHL • Quantitative JAK2 assessment in myelofibrosis patients undergoing allografting • Cost of blood and platelet studies –how much does it cost a hospital holistically to transfuse these cellular products • Teasing out biological factors of CD20 positive myeloma. • Is CD38 a predictor for indolent mantle cell lymphoma. Biological dissection of this cohort is being undertaken. Dr Neil Came • Immunohistochemical study of the plasma cell and B-lymphoid compartments in all cases of Waldenström Macroglobulinemia at PMCC and RMH • Immunohistochemical and Flow Cytometretric Evaluation of CD5-negative B-cell Lymphoma. • Phenotypic and Molecular Characterisation of Clonogenic Multiple Myeloma Precursor Cells (collaboration with HITRL). • Plasma cell Immunophenotyping by Flow Cytometry. • Validation of eight colour flow cytometry in leukaemia, MDS, lymphoma and myeloma. Dr Alex Dobrovic • Translational and clinical research into cancers including breast, lung, colorectal and urological cancers and haematological malignancies. • Identification of predictive markers enabling appropriate stratification of patients for individualised treatment. • Development of clinical diagnostics. • Adoption of novel molecular platforms and methodologies for genetic and epigenetic analysis. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Grants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
